{"id":"https://openalex.org/W4393093802","doi":"https://doi.org/10.1158/1538-7445.am2024-7539","title":"Abstract 7539: First-in-class anti-PVR mAb NTX1088 advancing through Phase I: Safe and potent in restoring DNAM1 expression to enhance antitumor immunity","display_name":"Abstract 7539: First-in-class anti-PVR mAb NTX1088 advancing through Phase I: Safe and potent in restoring DNAM1 expression to enhance antitumor immunity","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393093802","doi":"https://doi.org/10.1158/1538-7445.am2024-7539"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-7539","doi":"https://doi.org/10.1158/1538-7445.am2024-7539","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-7539","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074978291","display_name":"Anas Atieh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anas Atieh","raw_affiliation_strings":["1Nectin Therapeutics, Ltd., Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Ltd., Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113150167","display_name":"Akram Obeidat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akram Obeidat","raw_affiliation_strings":["1Nectin Therapeutics, Ltd., Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Ltd., Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003025980","display_name":"Alon Vitenshtein","orcid":"https://orcid.org/0000-0001-9914-9726","observed_orcids":["https://orcid.org/0000-0001-9914-9726"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alon Vitenshtein","raw_affiliation_strings":["1Nectin Therapeutics, Ltd., Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Ltd., Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007968346","display_name":"Guy Cinamon","orcid":"https://orcid.org/0000-0002-6988-1817","observed_orcids":["https://orcid.org/0000-0002-6988-1817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guy Cinamon","raw_affiliation_strings":["1Nectin Therapeutics, Ltd., Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Ltd., Jerusalem, Israel;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082520283","display_name":"Keren Paz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keren Paz","raw_affiliation_strings":["2Nectin Therapeutics, Ltd., Fort Lee, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Nectin Therapeutics, Ltd., Fort Lee, NJ;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064131245","display_name":"Tihana Lenac Rovi\u0161","orcid":"https://orcid.org/0000-0002-3299-1334","observed_orcids":["https://orcid.org/0000-0002-3299-1334"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tihana Rovi\u0161","raw_affiliation_strings":["3MEDRI, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3MEDRI, Rijeka, Croatia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044025083","display_name":"Paola Kucan Brilc","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paola Brilc","raw_affiliation_strings":["3MEDRI, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3MEDRI, Rijeka, Croatia;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035583924","display_name":"Ofer Mandelboim","orcid":"https://orcid.org/0000-0002-9354-1855","observed_orcids":["https://orcid.org/0000-0002-9354-1855"]},"institutions":[{"id":"https://openalex.org/I197251160","display_name":"Hebrew University of Jerusalem","ror":"https://ror.org/03qxff017","country_code":"IL","type":"education","lineage":["https://openalex.org/I197251160"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Ofer Mandelboim","raw_affiliation_strings":["4Hebrew University, Jerusalem, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Hebrew University, Jerusalem, Israel","institution_ids":["https://openalex.org/I197251160"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038051461","display_name":"Stipan Jonji\u0107","orcid":"https://orcid.org/0000-0001-5003-3108","observed_orcids":["https://orcid.org/0000-0001-5003-3108"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stipan Jonjic","raw_affiliation_strings":["3MEDRI, Rijeka, Croatia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3MEDRI, Rijeka, Croatia;","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Pini Tsukerman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pini Tsukerman","raw_affiliation_strings":["1Nectin Therapeutics, Ltd., Jerusalem, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Ltd., Jerusalem, Israel;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"7539","last_page":"7539"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd155","display_name":"CD155","score":0.9760000109672546},{"id":"https://openalex.org/keywords/tigit","display_name":"TIGIT","score":0.9120000004768372},{"id":"https://openalex.org/keywords/cd96","display_name":"CD96","score":0.8100000023841858},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8240000009536743},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.8999999761581421},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.5690000057220459},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7689999938011169},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.5669999718666077},{"id":"https://openalex.org/keywords/t-cells","display_name":"T cells","score":0.8149999976158142},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.5659999847412109},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4779999852180481},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7350000143051147},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7250000238418579}],"concepts":[{"id":"https://openalex.org/C2779341262","wikidata":"https://www.wikidata.org/wiki/Q182581","display_name":"Immunity","level":3,"score":0.5773019790649414},{"id":"https://openalex.org/C90559484","wikidata":"https://www.wikidata.org/wiki/Q778379","display_name":"Expression (computer science)","level":2,"score":0.49336376786231995},{"id":"https://openalex.org/C2777212361","wikidata":"https://www.wikidata.org/wiki/Q5127848","display_name":"Class (philosophy)","level":2,"score":0.4848693311214447},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40849220752716064},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39055120944976807},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.353353887796402},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33751776814460754},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.22583067417144775},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.118745356798172},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.06059551239013672},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-7539","doi":"https://doi.org/10.1158/1538-7445.am2024-7539","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2024-7539","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362545139","https://openalex.org/W4307906976","https://openalex.org/W4206777282","https://openalex.org/W4200217117","https://openalex.org/W4282941334","https://openalex.org/W4308377055","https://openalex.org/W3213939668","https://openalex.org/W7148649001","https://openalex.org/W7162525655","https://openalex.org/W4404064130"],"abstract_inverted_index":{"Abstract":[0],"NTX1088,":[1],"a":[2,11,64,86,95,111,117,215,230,241,259,304,324,338,343],"first-in-class":[3],"anti-PVR":[4,425],"(CD155)":[5],"mAb,":[6,73,298],"is":[7,61,94,116,145,229,361,367,391],"currently":[8,362],"evaluated":[9],"in":[10,68,76,140,205,327,399,435],"Phase":[12,430],"1,":[13],"open-label,":[14],"multi-center":[15],"study":[16],"(NCT05378425).":[17],"The":[18],"trial":[19,360],"initiated":[20],"at":[21,110],"MD":[22],"Anderson":[23],"Cancer":[24,451,469],"Center,":[25],"and":[26,41,50,57,67,104,158,164,179,201,224,253,267,326,364,433],"was":[27,211,273,285,289],"expanded":[28],"into":[29],"additional":[30],"sites,":[31],"including":[32,379],"City":[33],"of":[34,166,191,281,301,372,377,382,395,446],"Hope,":[35],"Ochsner":[36],"Health,":[37],"Sheba":[38],"Medical":[39,43],"Center":[40],"Hadassah":[42],"Center.":[44],"Study":[45],"objectives":[46],"are":[47],"safety,":[48],"dose-finding,":[49],"efficacy":[51],"with":[52,70,78,131,149,171,291,295,329],"focus":[53],"on":[54,122,156,348,386],"pharmacokinetics,":[55],"pharmacodynamics,":[56],"biomarker":[58,365],"discovery.":[59],"NTX1088":[60,93,184,228,243,272,288,317,336,375,427],"investigated":[62,315],"as":[63,214,240,323],"single":[65,112],"agent":[66],"combination":[69,328],"the":[71,150,172,279,296,380,392,447],"anti-PD1":[72],"pembrolizumab":[74],"(Keytruda)":[75],"patients":[77],"advanced":[79],"solid":[80],"malignancies.":[81],"Ongoing":[82],"dose":[83,91],"escalation":[84],"demonstrates":[85],"safe":[87],"profile":[88],"across":[89],"ascending":[90],"levels.":[92],"high":[96],"affinity":[97],"humanized":[98,310],"IgG4-S228P":[99],"mAb":[100,426],"that":[101],"binds":[102],"PVR":[103,126,168,182,333],"blocks":[105],"all":[106],"known":[107],"interacting":[108],"receptors":[109],"nM":[113],"EC50.":[114],"PVR,":[115],"highly":[118],"upregulated":[119],"membrane":[120],"protein":[121],"numerous":[123],"tumor":[124,262,307,320,355],"cells.":[125,207,283,389],"expression":[127,385,438],"has":[128,185,337],"been":[129],"associated":[130],"worse":[132],"patient":[133],"outcome,":[134],"due":[135],"to":[136,162,219,250,258,275,278,351,439],"its":[137,225,349],"central":[138],"role":[139],"immune":[141,174,193,206,221,246,282,388],"suppression.":[142],"PVR\u2019s":[143],"impact":[144],"mediated":[146],"through":[147,189,429],"interaction":[148],"key":[151,216],"stimulatory":[152],"receptor,":[153],"DNAM1":[154,192,209,277,383,397,437],"(CD226),":[155],"T":[157],"NK":[159],"cells,":[160],"leading":[161,257],"internalization":[163],"degradation":[165],"DNAM1.":[167],"also":[169],"interacts":[170],"inhibitory":[173,203],"checkpoint":[175,222],"receptors,":[176],"TIGIT,":[177,199,251],"CD96":[178,200],"KIR2DL5A.":[180],"Blocking":[181],"by":[183,227,236,335],"multiple":[186,354],"immune-stimulating":[187],"roles,":[188],"restoration":[190,226,381],"activation":[194],"function,":[195],"while":[196],"simultaneously":[197,352],"neutralizing":[198],"KIR2DL5A":[202],"signals":[204],"Importantly,":[208,270],"downmodulation":[210],"recently":[212],"identified":[213],"resistance":[217],"mechanism":[218],"approved":[220],"inhibitors,":[223],"novel":[231],"MoA,":[232],"not":[233],"demonstrated":[234,303],"previously":[235],"other":[237],"therapies.In":[238],"vitro,":[239],"monotherapy,":[242],"significantly":[244],"increased":[245],"cell":[247,263],"activation,":[248],"superior":[249],"CD112R,":[252],"PD1":[254,292,330],"antibody":[255],"blockade,":[256],"greater":[260],"immune-mediated":[261,306],"killing,":[264],"IFN\u03b3":[265],"secretion,":[266],"CD137":[268],"induction.":[269],"only":[271],"able":[274],"restore":[276],"surface":[280,384,396],"Synergy":[284],"obtained":[286],"when":[287],"combined":[290],"blockers,":[293],"or":[294],"anti-CD112R":[297],"NTX2R13.Syngeneic":[299],"models":[300,313],"PVRK.O,":[302],"complete":[305],"regression.":[308],"Numerous":[309],"murine":[311],"xenograft":[312],"were":[314],"whereby":[316],"exhibited":[318],"robust":[319],"growth":[321],"inhibition":[322],"standalone":[325],"blockade.In":[331],"conclusion,":[332],"blockade":[334],"remarkable":[339],"pre-clinical":[340],"efficacy,":[341],"suggesting":[342],"potential":[344],"clinical":[345,400],"breakthrough,":[346],"based":[347],"ability":[350],"overcome":[353],"escape":[356],"mechanisms.":[357],"First-in-human":[358],"(FIH)":[359],"ongoing":[363],"analysis":[366],"showing":[368],"initial":[369],"mechanistic":[370],"proof":[371],"concept":[373],"for":[374,450],"mode":[376],"action,":[378],"patients\u2019":[387],"This":[390],"first":[393],"case":[394],"elevation":[398],"settings.":[401],"Citation":[402],"Format:":[403],"Anas":[404],"Atieh,":[405],"Akram":[406],"Obeidat,":[407],"Alon":[408],"Vitenshtein,":[409],"Guy":[410],"Cinamon,":[411],"Keren":[412],"Paz,":[413],"Tihana":[414],"Rovi\u0161,":[415],"Paola":[416],"Brilc,":[417],"Ofer":[418],"Mandelboim,":[419],"Stipan":[420],"Jonjic,":[421],"Pini":[422],"Tsukerman.":[423],"First-in-class":[424],"advancing":[428],"I:":[431],"Safe":[432],"potent":[434],"restoring":[436],"enhance":[440],"antitumor":[441],"immunity":[442],"[abstract].":[443],"In:":[444],"Proceedings":[445],"American":[448],"Association":[449],"Research":[452],"Annual":[453],"Meeting":[454],"2024;":[455],"Part":[456],"1":[457],"(Regular":[458],"Abstracts);":[459],"2024":[460],"Apr":[461],"5-10;":[462],"San":[463],"Diego,":[464],"CA.":[465],"Philadelphia":[466],"(PA):":[467],"AACR;":[468],"Res":[470],"2024;84(6_Suppl):Abstract":[471],"nr":[472],"7539.":[473]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2024-03-23T00:00:00"}